Product Highlight - Nilemdo
14 Sep 2023
Add On to Take Back Control: A first-in-class oral, once-daily LDL-C lowering therapy1
- NILEMDO® delivered a significant 17-28% reduction in LDL-C**2-5
- Well tolerated in clinical studies and limited musculoskeletal side effect1-5
- Can be taken with or without food1
** vs placebo, on top of maximally tolerated statins with or without other lipid-lowering therapies. An up to 17% LDL-C reduction on top of maximally-tolerated statin therapy with around 50% of studied patients on high-intensity statins.2,4 An up to 28% LDL-C reduction was observed in patients on no statin or very low-intensity statin therapy, with or without other non-statin lipid-lowering therapies.3,5
References:
1. NILEMDO®. HK Prescribing Information Apr 2023.
2. Goldberg AC et al. JAMA. 2019; 322(18): 1780-1788.
3. Laufs U et al. J Am Heart Assoc. 2019; 8:e011662.
4. Ray KK et al. N Engl J Med. 2019; 380: 1022-1032.
5. Ballantyne CM et al. Atherosclerosis. 2018; 277: 195-203.
HK-DAI-NN-2307006; Date of Approval: Jul 2023
DAIICHI SANKYO HONG KONG LIMITED
Unit 1205, 12F, Sino Plaza, 255-257 Gloucester Rd, Causeway Bay
Tel: (+852) 2868 9072 • Fax: (+852) 2801 4341
https://www.daiichisankyo.com.hk/Enquiry
